 |
인쇄하기
취소
|
Boryung eager to license out novel angiotensin II receptor antagonist
With its new angiotensin II receptor blocker, Fimasartan, Boryung Pharm is seeking partners that can progress further clinical trial and market in US or EU in the future.
Fimasartan is a novel, non-peptide angiotensin II receptor antagonist with a selective AT1 receptor blockade effect, currently being developed as an antihypertensive agent by Boryung Pharm.
Phase III clinical trial is u...
Fimasartan is a novel, non-peptide angiotensin II receptor antagonist with a selective AT1 receptor blockade effect, currently being developed as an antihypertensive agent by Boryung Pharm.
Phase III clinical trial is u...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.